Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a two-arm, randomised, double-blind, phase 3 trial.

Mullane KM, Morrison VA, Camacho LH, Arvin A, McNeil SA, Durrand J, Campbell B, Su SC, Chan ISF, Parrino J, Kaplan SS, Popmihajlov Z, Annunziato PW; V212 Protocol 011 Trial Team.

Lancet Infect Dis. 2019 Sep;19(9):1001-1012. doi: 10.1016/S1473-3099(19)30310-X. Epub 2019 Aug 6. Erratum in: Lancet Infect Dis. 2019 Aug 23;:.

PMID:
31399378
2.

Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trial.

Winston DJ, Mullane KM, Cornely OA, Boeckh MJ, Brown JW, Pergam SA, Trociukas I, Žák P, Craig MD, Papanicolaou GA, Velez JD, Panse J, Hurtado K, Fernsler DA, Stek JE, Pang L, Su SC, Zhao Y, Chan ISF, Kaplan SS, Parrino J, Lee I, Popmihajlov Z, Annunziato PW, Arvin A; V212 Protocol 001 Trial Team.

Lancet. 2018 May 26;391(10135):2116-2127. doi: 10.1016/S0140-6736(18)30631-7. Epub 2018 May 24.

PMID:
29856344
3.

Herpes zoster vaccine live: A 10 year review of post-marketing safety experience.

Willis ED, Woodward M, Brown E, Popmihajlov Z, Saddier P, Annunziato PW, Halsey NA, Gershon AA.

Vaccine. 2017 Dec 19;35(52):7231-7239. doi: 10.1016/j.vaccine.2017.11.013. Epub 2017 Nov 22. Review.

4.

Varicella-zoster virus-specific antibody responses in 50-59-year-old recipients of zoster vaccine.

Levin MJ, Schmader KE, Gnann JW, McNeil SA, Vesikari T, Betts RF, Keay S, Stek JE, Bundick ND, Su SC, Zhao Y, Li X, Chan IS, Annunziato PW, Parrino J.

J Infect Dis. 2013 Nov 1;208(9):1386-90. doi: 10.1093/infdis/jit342. Epub 2013 Aug 1.

5.

Safety and immunogenicity of heat-treated zoster vaccine (ZVHT) in immunocompromised adults.

Mullane KM, Winston DJ, Wertheim MS, Betts RF, Poretz DM, Camacho LH, Pergam SA, Mullane MR, Stek JE, Sterling TM, Zhao Y, Manoff SB, Annunziato PW.

J Infect Dis. 2013 Nov 1;208(9):1375-85. doi: 10.1093/infdis/jit344. Epub 2013 Aug 1.

PMID:
23908479
6.

Safety of zoster vaccine in elderly adults following documented herpes zoster.

Morrison VA, Oxman MN, Levin MJ, Schmader KE, Guatelli JC, Betts RF, Gelb LD, Pachucki CT, Keay SK, Menzies B, Griffin MR, Kauffman CA, Marques AR, Toney JF, Simberkoff MS, Serrao R, Arbeit RD, Gnann JW, Greenberg RN, Holodniy M, Keitel WA, Yeh SS, Davis LE, Crawford GE, Neuzil KM, Johnson GR, Zhang JH, Harbecke R, Chan IS, Keller PM, Williams HM, Boardman KD, Silber JL, Annunziato PW; Shingles Prevention Study Group.

J Infect Dis. 2013 Aug 15;208(4):559-63. doi: 10.1093/infdis/jit182. Epub 2013 Apr 30.

7.

Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years.

Schmader KE, Levin MJ, Gnann JW Jr, McNeil SA, Vesikari T, Betts RF, Keay S, Stek JE, Bundick ND, Su SC, Zhao Y, Li X, Chan IS, Annunziato PW, Parrino J.

Clin Infect Dis. 2012 Apr;54(7):922-8. doi: 10.1093/cid/cir970. Epub 2012 Jan 30.

8.

Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥60 years of age.

Vermeulen JN, Lange JM, Tyring SK, Peters PH, Nunez M, Poland G, Levin MJ, Freeman C, Chalikonda I, Li J, Smith JG, Caulfield MJ, Stek JE, Chan IS, Vessey R, Schödel FP, Annunziato PW, Schlienger K, Silber JL.

Vaccine. 2012 Jan 20;30(5):904-10. doi: 10.1016/j.vaccine.2011.11.096. Epub 2011 Dec 7.

PMID:
22154769
9.

Safety and tolerability of zoster vaccine in adults ≥60 years old.

Murray AV, Reisinger KS, Kerzner B, Stek JE, Sausser TA, Xu J, Wang WW, Chan IS, Annunziato PW, Parrino J.

Hum Vaccin. 2011 Nov;7(11):1130-6. doi: 10.4161/hv.7.11.17982. Epub 2011 Nov 1.

10.

Concomitant administration of zoster and pneumococcal vaccines in adults ≥60 years old.

MacIntyre CR, Egerton T, McCaughey M, Parrino J, Campbell BV, Su SC, Pagnoni MF, Stek JE, Xu J, Annunziato PW, Chan IS, Silber JL.

Hum Vaccin. 2010 Nov;6(11):894-902. Epub 2010 Nov 1.

PMID:
20980796
11.

Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial.

Simberkoff MS, Arbeit RD, Johnson GR, Oxman MN, Boardman KD, Williams HM, Levin MJ, Schmader KE, Gelb LD, Keay S, Neuzil K, Greenberg RN, Griffin MR, Davis LE, Morrison VA, Annunziato PW; Shingles Prevention Study Group.

Ann Intern Med. 2010 May 4;152(9):545-54. doi: 10.7326/0003-4819-152-9-201005040-00004.

PMID:
20439572
12.

Safety and tolerability of a high-potency zoster vaccine in adults >/= 50 or years of age.

Tyring SK, Diaz-Mitoma F, Padget LG, Nunez M, Poland G, Cassidy WM, Bundick ND, Li J, Chan IS, Stek JE, Annunziato PW; Protocol 009 Study Group.

Vaccine. 2007 Feb 26;25(10):1877-83. Epub 2006 Oct 30.

PMID:
17227688
13.

A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.

Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, Arbeit RD, Simberkoff MS, Gershon AA, Davis LE, Weinberg A, Boardman KD, Williams HM, Zhang JH, Peduzzi PN, Beisel CE, Morrison VA, Guatelli JC, Brooks PA, Kauffman CA, Pachucki CT, Neuzil KM, Betts RF, Wright PF, Griffin MR, Brunell P, Soto NE, Marques AR, Keay SK, Goodman RP, Cotton DJ, Gnann JW Jr, Loutit J, Holodniy M, Keitel WA, Crawford GE, Yeh SS, Lobo Z, Toney JF, Greenberg RN, Keller PM, Harbecke R, Hayward AR, Irwin MR, Kyriakides TC, Chan CY, Chan IS, Wang WW, Annunziato PW, Silber JL; Shingles Prevention Study Group.

N Engl J Med. 2005 Jun 2;352(22):2271-84.

14.

Varicella zoster virus in human and rat tissue specimens.

Annunziato PW, Lungu O, Panagiotidis C.

Arch Virol Suppl. 2001;(17):135-42. Review.

PMID:
11339542
15.

Varicella-zoster virus proteins in skin lesions: implications for a novel role of ORF29p in chickenpox.

Annunziato PW, Lungu O, Panagiotidis C, Zhang JH, Silvers DN, Gershon AA, Silverstein SJ.

J Virol. 2000 Feb;74(4):2005-10.

16.

Varicella-zoster virus: latency and reactivation.

Lungu O, Annunziato PW.

Contrib Microbiol. 1999;3:61-75. Review. No abstract available.

PMID:
10599521
17.

Aberrant intracellular localization of Varicella-Zoster virus regulatory proteins during latency.

Lungu O, Panagiotidis CA, Annunziato PW, Gershon AA, Silverstein SJ.

Proc Natl Acad Sci U S A. 1998 Jun 9;95(12):7080-5.

18.

Herpes simplex virus infections.

Annunziato PW, Gershon A.

Pediatr Rev. 1996 Dec;17(12):415-23; quiz 424. Review. No abstract available.

PMID:
8973122
19.

Reactivated and latent varicella-zoster virus in human dorsal root ganglia.

Lungu O, Annunziato PW, Gershon A, Staugaitis SM, Josefson D, LaRussa P, Silverstein SJ.

Proc Natl Acad Sci U S A. 1995 Nov 21;92(24):10980-4.

20.
21.

Comparison of a three-component acellular pertussis vaccine with a whole-cell pertussis vaccine in 4- through 6-year-old children. Elmwood Pediatric Associates, Pennridge Pediatric Associates.

Annunziato PW, Rothstein EP, Bernstein HH, Blatter MM, Reisinger KS, Pichichero ME.

Arch Pediatr Adolesc Med. 1994 May;148(5):503-7.

PMID:
8180641
22.

The epidemiology of pediatric HIV-1 infection.

Annunziato PW, Frenkel LM.

Pediatr Ann. 1993 Jul;22(7):401-5. Review.

PMID:
8414693

Supplemental Content

Loading ...
Support Center